Matches in SemOpenAlex for { <https://semopenalex.org/work/W4206174569> ?p ?o ?g. }
Showing items 1 to 76 of
76
with 100 items per page.
- W4206174569 endingPage "S99" @default.
- W4206174569 startingPage "S99" @default.
- W4206174569 abstract "Avelumab is a fully human IgG1 antibody that targets PD-L1. Avelumab is approved in Finland as monotherapy for first-line maintenance treatment of adult patients with locally advanced or metastatic urothelial carcinoma that has not progressed during platinum-based chemotherapy. This study aimed to assess the cost-effectiveness of avelumab + best supportive care (BSC) versus BSC alone in the aforementioned indication in the Finnish healthcare setting. Using a Finnish healthcare perspective, a cost-utility analysis was conducted by building a 3-state partitioned survival model, which was used to estimate costs, effects, and an incremental cost-effectiveness ratio (ICER) during a base case time horizon of 25 years. Efficacy, safety, and utility parameters were derived from the phase 3 study JAVELIN Bladder 100, which was the primary data source, together with Finnish expert input and cost literature. Clinical study results were extrapolated with parametric survival curves, including spline-based models for progression-free survival. Both costs (2020 euros) and effects were discounted at a 3% annual discount rate. In addition, scenario analyses and a probabilistic sensitivity analysis were conducted to assess the effect and magnitude of uncertainty. In the base case analysis, avelumab + BSC achieved 1.00 additional life-year (3.94 vs 2.95) and 0.63 (2.44 vs 1.82) quality-adjusted life-years (QALYs) compared with BSC alone. The ICER was <3 times the GDP per capita per QALY gained. Sensitivity analyses show that the relative dose intensity of avelumab, along with parameters relating to subsequent treatment lines, have a significant impact on cost-effectiveness. Avelumab provides a significant clinical improvement in a patient population affected by a severe form of cancer that usually carries a relatively poor prognosis. In addition, avelumab is a potentially cost-effective treatment option compared to BSC alone, in patients eligible for first-line maintenance treatment of locally advanced or metastatic urothelial cancer in the Finnish healthcare setting." @default.
- W4206174569 created "2022-01-25" @default.
- W4206174569 creator A5005048553 @default.
- W4206174569 creator A5051178751 @default.
- W4206174569 creator A5079320079 @default.
- W4206174569 creator A5085170205 @default.
- W4206174569 creator A5090712442 @default.
- W4206174569 date "2022-01-01" @default.
- W4206174569 modified "2023-10-13" @default.
- W4206174569 title "POSC66 Cost-Effectiveness of Avelumab as First-Line Maintenance Treatment for Locally Advanced or Metastatic Urothelial Carcinoma in Finland" @default.
- W4206174569 doi "https://doi.org/10.1016/j.jval.2021.11.471" @default.
- W4206174569 hasPublicationYear "2022" @default.
- W4206174569 type Work @default.
- W4206174569 citedByCount "2" @default.
- W4206174569 countsByYear W42061745692023 @default.
- W4206174569 crossrefType "journal-article" @default.
- W4206174569 hasAuthorship W4206174569A5005048553 @default.
- W4206174569 hasAuthorship W4206174569A5051178751 @default.
- W4206174569 hasAuthorship W4206174569A5079320079 @default.
- W4206174569 hasAuthorship W4206174569A5085170205 @default.
- W4206174569 hasAuthorship W4206174569A5090712442 @default.
- W4206174569 hasBestOaLocation W42061745691 @default.
- W4206174569 hasConcept C112930515 @default.
- W4206174569 hasConcept C121608353 @default.
- W4206174569 hasConcept C126322002 @default.
- W4206174569 hasConcept C142724271 @default.
- W4206174569 hasConcept C143998085 @default.
- W4206174569 hasConcept C177713679 @default.
- W4206174569 hasConcept C2776125615 @default.
- W4206174569 hasConcept C2776738588 @default.
- W4206174569 hasConcept C2777381376 @default.
- W4206174569 hasConcept C2777701055 @default.
- W4206174569 hasConcept C2780057760 @default.
- W4206174569 hasConcept C2780352672 @default.
- W4206174569 hasConcept C2911057145 @default.
- W4206174569 hasConcept C3019080777 @default.
- W4206174569 hasConcept C3019882237 @default.
- W4206174569 hasConcept C515549039 @default.
- W4206174569 hasConcept C71924100 @default.
- W4206174569 hasConceptScore W4206174569C112930515 @default.
- W4206174569 hasConceptScore W4206174569C121608353 @default.
- W4206174569 hasConceptScore W4206174569C126322002 @default.
- W4206174569 hasConceptScore W4206174569C142724271 @default.
- W4206174569 hasConceptScore W4206174569C143998085 @default.
- W4206174569 hasConceptScore W4206174569C177713679 @default.
- W4206174569 hasConceptScore W4206174569C2776125615 @default.
- W4206174569 hasConceptScore W4206174569C2776738588 @default.
- W4206174569 hasConceptScore W4206174569C2777381376 @default.
- W4206174569 hasConceptScore W4206174569C2777701055 @default.
- W4206174569 hasConceptScore W4206174569C2780057760 @default.
- W4206174569 hasConceptScore W4206174569C2780352672 @default.
- W4206174569 hasConceptScore W4206174569C2911057145 @default.
- W4206174569 hasConceptScore W4206174569C3019080777 @default.
- W4206174569 hasConceptScore W4206174569C3019882237 @default.
- W4206174569 hasConceptScore W4206174569C515549039 @default.
- W4206174569 hasConceptScore W4206174569C71924100 @default.
- W4206174569 hasIssue "1" @default.
- W4206174569 hasLocation W42061745691 @default.
- W4206174569 hasOpenAccess W4206174569 @default.
- W4206174569 hasPrimaryLocation W42061745691 @default.
- W4206174569 hasRelatedWork W2510722740 @default.
- W4206174569 hasRelatedWork W2586210842 @default.
- W4206174569 hasRelatedWork W2899953288 @default.
- W4206174569 hasRelatedWork W2908319635 @default.
- W4206174569 hasRelatedWork W2997640121 @default.
- W4206174569 hasRelatedWork W3096852241 @default.
- W4206174569 hasRelatedWork W4205638399 @default.
- W4206174569 hasRelatedWork W4206174569 @default.
- W4206174569 hasRelatedWork W4230187632 @default.
- W4206174569 hasRelatedWork W4310045802 @default.
- W4206174569 hasVolume "25" @default.
- W4206174569 isParatext "false" @default.
- W4206174569 isRetracted "false" @default.
- W4206174569 workType "article" @default.